You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD1/PD-L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

Not yet recruiting
  • Lung Neoplasm
  • +2 more
  • Tumor samples
  • Bordeaux, France
    CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
Aug 28, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Mar 28, 2022

Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

Recruiting
  • Oncology
  • +2 more
  • UV1
  • +2 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
Aug 15, 2022

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • Lung Cancer
    • Beijing, China
      Peking Union Medical College Hospital
    Mar 31, 2022

    Solid Tumor, NSCLC, Cervical Cancer Trial in China (Afuresertib, Nab paclitaxel, Docetaxel)

    Recruiting
    • Solid Tumor
    • +5 more
    • Beijing, Beijing, China
    • +4 more
    Jul 15, 2022

    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • HAIC
    • +8 more
    • Quanzhou, Fujian, China
    • +1 more
    Jan 26, 2023

    Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)

    Not yet recruiting
    • Non Small Cell Lung Cancer Metastatic
    • Pembrolizumab in Combination with Plinabulin and Docetaxel
    • (no location specified)
    Oct 28, 2022

    Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • TACE
    • +8 more
    • Quanzhou, Fujian, China
    • +3 more
    Jan 29, 2023

    Melanoma, Renal Cell Carcinoma, Brain Metastases Trial in New Haven (Pembrolizumab, Lenvatinib)

    Recruiting
    • Melanoma
    • +6 more
    • New Haven, Connecticut
      Yale University
    Feb 18, 2022

    Merkel Cell Carcinoma Trial in Stanford (Pembrolizumab, Radiation Therapy)

    Terminated
    Has Results
    • Merkel Cell Carcinoma
    • Stanford, California
      Stanford University
    Aug 5, 2021

    Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

    Not yet recruiting
    • Metastatic Pancreatic Cancer
    • Durvalumab
    • Rintatolimod
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus MC
    Jun 23, 2023

    Gut Microbiota and Cancer Immunotherapy Response

    Recruiting
    • Non-Small Cell Lung Cancer
    • Response to anti-PD-1/PD-L1
    • Non-response to anti-PD-1/PD-L1
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Aug 12, 2021

    Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

    Not yet recruiting
    • Extensive-Stage Small Cell Lung Cancer
    • Beijing, China
      Chinese PLA General Hospital
    Aug 18, 2022

    Advanced NSCLC Trial in Nanjing (AK104, Docetaxel)

    Recruiting
    • Advanced Non-small Cell Lung Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital
    Mar 24, 2022

    Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital ( Site 3700)
    Jan 31, 2023

    Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

    Active, not recruiting
    • Extranodal NK/T Cell Lymphoma, Nasal Type
    • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
    • Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 10, 2022

    Advanced Solid Tumor Trial (HLX43)

    Not yet recruiting
    • Advanced Solid Tumor
    • (no location specified)
    Oct 30, 2023

    NSCLC Trial (PM8002, Placebo, Carboplatin)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Feb 23, 2023

    Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

    Not yet recruiting
    • Carcinoma, Hepatocellular
      • (no location specified)
      May 16, 2022

      NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Capsulized Fecal Microbiota Transplant
      • +2 more
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University
      Aug 12, 2021

      NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • Tumor treating fields（EFE-P100）
      • Docetaxel injection
      • Shanghai, China
        Shanghai Pulmonary Hospital
      Dec 21, 2022